Pre-Market Money Movers

by @tabber

NOV 19, 2026

SLS — -23% premarket on $150M dilutive public offering

SLS−23% down

SELLAS Life Sciences plunged about 23% premarket after pricing a $150 million underwritten public offering. The dilutive raise lands just days after the stock ran up on Phase 3 leukemia data, and the offering size is large relative to the company's market value. Sellers are pricing in the dilution, not the pipeline.

Read full analysis on stockmarketwatch.com ↗
Useful?